慢性C型肝炎
Chronic hepatitis C Treatment of adults with HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh class A) who have:
(1) genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor
(2) genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor

Antiretrovials Antivirals
NS5B RNA Polymerase Inhibitor; NS5A Inhibitor; NS3/4A Inhibitor

1. Hypersensitivity to sofosbuvir, velpatasvir, voxilaprevir.
2. Concurrent use with rifampin.

1. Adverse events were not observed in animal reproduction studies using individual components of this combination.
2. When HCV infection is detected during pregnancy, treatment should be deferred until after delivery.

It is not known if sofosbuvir, velpatasvir, or voxilaprevir are present in human breast milk.

1. Central nervous system: Headache, fatigue
2. Gastrointestinal: Diarrhea, nausea
3. Hepatic: Increased serum bilirubin

Genotype 1:
1. Non-NS5A inhibitor, sofosbuvir-containing regimen (genotype 1a only): 1 tablet once daily for 12 weeks.
2. NS5A inhibitor direct-acting antiviral–experienced (excluding glecaprevir/pibrentasvir failures): 1 tablet once daily for 12 weeks
3. Prior glecaprevir/pibrentasvir treatment failure: 1 tablet once daily for 12 weeks
4. Prior sofosbuvir/velpatasvir/voxilaprevir treatment failure: 1 tablet once daily in combination with ribavirin for 24 weeks
Genotype 2:
1. Sofosbuvir + NS5A inhibitor–experienced (excluding glecaprevir/pibrentasvir failures): 1 tablet once daily for 12 weeks
2. Prior glecaprevir/pibrentasvir treatment failure: 1 tablet once daily for 12 weeks
3. Prior sofosbuvir/velpatasvir/voxilaprevir treatment failure: 1 tablet once daily in combination with ribavirin for 24 weeks
Genotype 3:
1. Sofosbuvir + ribavirin-experienced (with or without peginterferon): 1 tablet once daily for 12 weeks
2. Direct-acting antiviral–experienced (including NS5A inhibitors except glecaprevir/pibrentasvir failures): 1 tablet once daily for 12 weeks
3. Prior glecaprevir/pibrentasvir treatment failure: 1 tablet once daily for 12 weeks
4. Prior sofosbuvir/velpatasvir/voxilaprevir treatment failure: 1 tablet once daily in combination with ribavirin for 24 weeks
Genotype 4, 5 or 6:
1. Direct-acting antiviral–experienced (including NS5A inhibitors except glecaprevir/pibrentasvir failures): 1 tablet once daily for 12 weeks
2. Prior glecaprevir/pibrentasvir treatment failure: 1 tablet once daily for 12 weeks
3. Prior sofosbuvir/velpatasvir/voxilaprevir treatment failure: 1 tablet once daily in combination with ribavirin for 24 weeks
Administration:
Administer with food

No dosage adjustment necessary.

Hepatic impairment prior to treatment initiation:
1. Mild impairment (Child-Pugh class A): No dosage adjustment necessary.
2. Moderate or severe impairment (Child-Pugh class B or C): Use is not recommended (due to higher voxilaprevir exposure).
Hepatotoxicity during treatment:
Discontinue use.

Please store in original packaging below 30 ℃.